S-1/A EX-FILING FEES 0001139685 333-292125 N/A N/A 0001139685 1 2026-01-17 2026-01-17 0001139685 10 2026-01-17 2026-01-17 0001139685 11 2026-01-17 2026-01-17 0001139685 12 2026-01-17 2026-01-17 0001139685 2 2026-01-17 2026-01-17 0001139685 3 2026-01-17 2026-01-17 0001139685 4 2026-01-17 2026-01-17 0001139685 5 2026-01-17 2026-01-17 0001139685 6 2026-01-17 2026-01-17 0001139685 7 2026-01-17 2026-01-17 0001139685 8 2026-01-17 2026-01-17 0001139685 9 2026-01-17 2026-01-17 0001139685 2026-01-17 2026-01-17 iso4217:USD xbrli:pure xbrli:shares

Ex-Filing Fees

CALCULATION OF FILING FEE TABLES

S-1

20/20 BIOLABS, INC.

Table 1: Newly Registered and Carry Forward Securities


Line Item Type	Security Type	Security Class Title	Notes	Fee Calculation Rule	Amount Registered	Proposed Maximum Offering Price Per Unit		Maximum Aggregate Offering Price		Fee Rate	Amount of Registration Fee

Newly Registered Securities
Fees to be Paid	Equity	Common Stock, $0.01 par value, to be issued to selling stockholders	(1)	457(a)	34,669	$	11.42	$	395,919.98	0.0001381	$	54.68
Fees Previously Paid	Equity	Common Stock, $0.01 par value, issued to selling stockholders	(2)	457(a)	4,967,249		11.42		56,725,983.58	0.0001381		7,833.86
Fees Previously Paid	Equity	Common Stock, $0.01 par value, issuable to selling stockholders upon conversion of Series A Preferred Stock	(3)	457(a)	846,368		11.42		9,665,522.56	0.0001381		1,334.81
Fees Previously Paid	Equity	Common Stock, $0.01 par value, issuable to selling stockholders upon conversion of Series A-1 Preferred Stock	(4)	457(a)	651,465		11.42		7,439,730.30	0.0001381		1,027.43
Fees Previously Paid	Equity	Common Stock, $0.01 par value, issuable to selling stockholders upon conversion of Series A-2 Preferred Stock	(5)	457(a)	442,402		11.42		5,052,230.84	0.0001381		697.71
Fees Previously Paid	Equity	Common Stock, $0.01 par value, issuable to selling stockholders upon conversion of Series B Preferred Stock	(6)	457(a)	1,471,487		11.42		16,804,381.54	0.0001381		2,320.69
Fees Previously Paid	Equity	Common Stock, $0.01 par value, issuable to selling stockholders upon conversion of Series C Preferred Stock	(7)	457(a)	1,204,040		11.42		13,750,136.80	0.0001381		1,898.89
Fees Previously Paid	Equity	Common Stock, $0.01 par value, issuable to selling stockholders upon conversion of Series D Preferred Stock	(8)	457(a)	101,565		11.42		1,159,872.30	0.0001381		160.18
Fees Previously Paid	Equity	Common Stock, $0.01 par value, issuable to selling stockholders upon conversion of secured convertible promissory note	(9)	457(a)	47,500		11.42		542,450.00	0.0001381		74.91
Fees Previously Paid	Equity	Common Stock, $0.01 par value, issuable to selling stockholders upon exercise of outstanding warrants	(10)	457(a)	62,500		11.42		713,750.00	0.0001381		98.57
Fees Previously Paid	Equity	Common Stock, $0.01 par value, issuable to selling stockholders upon exercise of warrants to be issued to selling stockholders	(11)	457(a)	5,196,643		11.42		59,345,663.06	0.0001381		8,195.64
Fees Previously Paid	Equity	Common Stock, $0.01 par value, to be issued to selling stockholders	(12)	457(a)	138,836	$	11.42	$	1,585,507.12	0.0001381	$	218.96

Total Offering Amounts:								$	173,181,148.08			23,916.33
Total Fees Previously Paid:												23,861.65
Total Fee Offsets:												0.00
Net Fee Due:											$	54.68

__________________________________________
Offering Note(s)

(1)

The proposed maximum offering price per unit has been estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(a) of the Securities Act of 1933, as amended, based solely on a third-party valuation in accordance with Rule 457(f)(2) under the Securities Act of 1933, as amended.

(2)

(3)

(4)

(5)

(6)

(7)

(8)

(9)

(10)

(11)

(12)

20/20 Biolabs, Inc. S-1/A